3,130 Shares in IQVIA Holdings Inc. $IQV Acquired by Citizens Financial Group Inc. RI

Citizens Financial Group Inc. RI acquired a new stake in IQVIA Holdings Inc. (NYSE:IQV) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 3,130 shares of the medical research company’s stock, valued at approximately $605,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. International Assets Investment Management LLC bought a new position in shares of IQVIA in the 4th quarter worth $27,000. Gilpin Wealth Management LLC bought a new stake in IQVIA during the 4th quarter valued at $27,000. CrossGen Wealth LLC bought a new stake in IQVIA during the 4th quarter valued at $28,000. Activest Wealth Management raised its holdings in IQVIA by 590.0% during the fourth quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock worth $31,000 after buying an additional 118 shares during the last quarter. Finally, Financial Freedom LLC bought a new position in shares of IQVIA in the first quarter valued at $25,000. Institutional investors own 89.62% of the company’s stock.

IQVIA Trading Up 4.0%

NYSE:IQV opened at $249.62 on Thursday. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71. The firm has a market cap of $41.09 billion, a price-to-earnings ratio of 30.97, a price-to-earnings-growth ratio of 2.04 and a beta of 1.18. IQVIA Holdings Inc. has a 52 week low of $154.50 and a 52 week high of $251.36. The firm has a 50-day moving average price of $210.23 and a two-hundred day moving average price of $186.82.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, topping the consensus estimate of $3.03 by $0.12. The firm had revenue of $4.37 billion for the quarter, compared to analysts’ expectations of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The company’s quarterly revenue was up 8.7% compared to the same quarter last year. During the same quarter last year, the firm earned $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, equities analysts expect that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA announced that its board has approved a share repurchase program on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to buy up to 6.8% of its shares through open market purchases. Shares repurchase programs are often a sign that the company’s management believes its stock is undervalued.

Analyst Ratings Changes

IQV has been the subject of several recent research reports. TD Cowen boosted their target price on shares of IQVIA from $233.00 to $288.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. Robert W. Baird lifted their price target on IQVIA from $252.00 to $287.00 and gave the company an “outperform” rating in a research note on Wednesday, July 29th. JPMorgan Chase & Co. boosted their price objective on IQVIA from $225.00 to $285.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. William Blair upgraded IQVIA to a “strong-buy” rating in a report on Tuesday, July 28th. Finally, Stifel Nicolaus lifted their target price on IQVIA from $220.00 to $276.00 and gave the company a “buy” rating in a research report on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $241.88.

Insiders Place Their Bets

In other news, insider Eric Sherbet sold 5,000 shares of the firm’s stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the completion of the sale, the insider directly owned 20,999 shares of the company’s stock, valued at $5,232,110.84. This trade represents a 19.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Bhavik Patel sold 1,855 shares of IQVIA stock in a transaction on Friday, July 31st. The stock was sold at an average price of $235.27, for a total value of $436,425.85. Following the sale, the insider owned 1,348 shares in the company, valued at $317,143.96. The trade was a 57.91% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 12,913 shares of company stock worth $3,098,793 over the last 90 days. Company insiders own 1.70% of the company’s stock.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.